15 October 2020 in Russian Journal of Skin and Venereal Diseases
IMPORTANCE: In 2019, the world faced a serious threat a new coronavirus infection (COVID-19) which entailed severe social and economic losses. Considering the massive spread of COVID-19 in 2020, recently, studying the methods of prevention used to prevent the spread of the disease is considered relevant. RESULTS: We have analyzed scientific publications devoted to the study of prevention in databases, such as Scopus, Web of Science, and CyberLeninka. Antiseptic drugs were of particular interest; thus, this article describes the nonspecific preventive measures with the use of miramistin antiseptic drug. This drug has a wide antimicrobial and antiviral spectrum of action. It has a bactericidal effect on aerobic and anaerobic bacteria, and their association on fungal microflora with significant influences on herpes viruses, human immunodeficiency, hepatitis, and sexually transmitted pathogens. Therefore, for many years, this drug is actively used as a means of prevention. Scientific evidence stating that miramistin can inactivate coronaviruses exists. The obtained data show that miramistin in 0.0001% concentration reduces the infectious activity of human coronavirus almost twice, and miramistin in 0.005% concentration and above completely neutralizes the infectious activity of human coronavirus. It has been proven that miramistin has an immunoadjuvant effect, which leads to increased protective reactions of the skin and enhances skin regeneration due to the activation of cellular and humoral immune responses. CONCLUSION: Miramistin preparation has the following important advantage: it has a selective effect on pathogens and does not have an adverse effect on body tissues.
15 August 2020 in Russian Journal of Skin and Venereal Diseases
МНМараках Марван Якин Нажи
BACKGROUND:Psoriasis is a chronic immune-mediated inflammatory skin disease. The goal of psoriasis therapy is to achieve long-term stable remission and improve the patients quality of life. Continuity of therapy is the basis for successful disease control. To achieve this goal, the most effective genetic engineered biological drugs are currently used. However, in some patients the biologicals demonstrated insufficient effectiveness. The presence of comorbidities, in particular metabolic syndrome in such cases, is one of the reasons for low therapeutic response. AIM:This study aimed to evaluate the therapeutic effectiveness of ustekinumab in psoriasis patients with metabolic syndrome after a long interruption and resumption of therapy. MATERIALS AND METODS:We observed 68 patients diagnosed with advanced plaque psoriasis. They were divided into two groups according to their body mass index and metabolic disorders. RESULTS:By week 24, 96.8% of the patients in group 1 and 91.6% in group 2 reached PASI 75. By week 48, 100% of the patients in group 1 and 86.1% in group 2 reached PASI 75. By week 76, PASI 75 was observed in 96.8% of patients receiving 45 mg of ustekinumab and in 83.3% of patients receiving 90 mg of ustekinumab. Treatment with ustekinumab was discontinued at week 76 due to economic factors. The therapy was discontinued for 36 weeks. By week 112, 86.7% of the patients in both groups had a relapse of psoriasis, which was assessed by the loss of therapeutic response. By week 124 (12 weeks after the resumption of therapy), PASI 75 was reached in 93.7% of the patients in group 1 and 77.7% in group 2. By week 136, all patients in group 1 had achieved PASI 75, and by week 128, 83.3% of patients in group 2 had PASI 75. CONCLUSIONS:In patients with psoriasis on ustekinumab therapy, a long-term (36 weeks) interruption and resumption of therapy is possible. However, in patients with comorbid pathology, effectiveness is dimi-nished; thus, new methods of pathogenetic therapy to correct metabolic disorders are needed.